Tags

Type your tag names separated by a space and hit enter

Serum levels of nesfatin-1 are increased in gestational diabetes mellitus.
Gynecol Endocrinol. 2017 Aug; 33(8):621-624.GE

Abstract

OBJECTIVE

To analyze the concentrations of nesfatin-1 in maternal and cord serum, to evaluate the expression of nesfatin-1 in subcutaneous adipose tissue (SAT) from pregnant women with gestational diabetes mellitus (GDM) and those with normal glucose tolerance (NGT).

METHODS

We studied a total of 50 GDM and 50 NGT subjects. The clinical features, serum nesfatin-1, homeostasis model assessment of insulin resistance (HOMA-IR), lipid profiles were measured at the third trimester of pregnancy. The expression of nesfatin-1 in the SAT was determined by western blot.

RESULTS

Compared with the NGT group, the GDM group showed greater levels of serum nesfatin-1, adipocyte fatty acid binding protein (AFABP), and leptin; a greater level of cord blood nesfatin-1; and a higher level of expression in SAT (p < 0.05 or p < 0.01). Fasting insulin (FI) (b = 0.317, p= 0.022) and body mass index (BMI) before delivery (b = 0.367, p=0.008) were independently associated with serum nesfatin-1. Nesfatin-1 was the independent risk factor for GDM.

CONCLUSIONS

The GDM group had higher levels of maternal serum and cord blood nesfatin-1, and greater nesfatin-1 expression in SAT. Nesfatin-1 is closely related to obesity and IR in pregnancy.

Authors+Show Affiliations

a Department of Endocrinology , Guangzhou , PR China. b Department of Obstetrics and Gynecology , The Third Affiliated Hospital of Guangzhou Medical University , Guangzhou , PR China , and.a Department of Endocrinology , Guangzhou , PR China.a Department of Endocrinology , Guangzhou , PR China.a Department of Endocrinology , Guangzhou , PR China.a Department of Endocrinology , Guangzhou , PR China.a Department of Endocrinology , Guangzhou , PR China.b Department of Obstetrics and Gynecology , The Third Affiliated Hospital of Guangzhou Medical University , Guangzhou , PR China , and.c Key Laboratory for Major Obstetric Diseases of Guangdong Higher Education Institutes , Guangzhou , PR China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28361552

Citation

Zhang, Ying, et al. "Serum Levels of Nesfatin-1 Are Increased in Gestational Diabetes Mellitus." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 33, no. 8, 2017, pp. 621-624.
Zhang Y, Lu JH, Zheng SY, et al. Serum levels of nesfatin-1 are increased in gestational diabetes mellitus. Gynecol Endocrinol. 2017;33(8):621-624.
Zhang, Y., Lu, J. H., Zheng, S. Y., Yan, J. H., Chen, L., Liu, X., Wu, W. Z., & Wang, F. (2017). Serum levels of nesfatin-1 are increased in gestational diabetes mellitus. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 33(8), 621-624. https://doi.org/10.1080/09513590.2017.1306849
Zhang Y, et al. Serum Levels of Nesfatin-1 Are Increased in Gestational Diabetes Mellitus. Gynecol Endocrinol. 2017;33(8):621-624. PubMed PMID: 28361552.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum levels of nesfatin-1 are increased in gestational diabetes mellitus. AU - Zhang,Ying, AU - Lu,Jia-Hui, AU - Zheng,Si-Yuan, AU - Yan,Jia-He, AU - Chen,Lin, AU - Liu,Xin, AU - Wu,Wei-Zhen, AU - Wang,Fang, Y1 - 2017/03/31/ PY - 2017/4/1/pubmed PY - 2018/5/23/medline PY - 2017/4/1/entrez KW - Adipocytokine KW - gestational diabetes mellitus KW - insulin resistance KW - nesfatin-1 SP - 621 EP - 624 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol. Endocrinol. VL - 33 IS - 8 N2 - OBJECTIVE: To analyze the concentrations of nesfatin-1 in maternal and cord serum, to evaluate the expression of nesfatin-1 in subcutaneous adipose tissue (SAT) from pregnant women with gestational diabetes mellitus (GDM) and those with normal glucose tolerance (NGT). METHODS: We studied a total of 50 GDM and 50 NGT subjects. The clinical features, serum nesfatin-1, homeostasis model assessment of insulin resistance (HOMA-IR), lipid profiles were measured at the third trimester of pregnancy. The expression of nesfatin-1 in the SAT was determined by western blot. RESULTS: Compared with the NGT group, the GDM group showed greater levels of serum nesfatin-1, adipocyte fatty acid binding protein (AFABP), and leptin; a greater level of cord blood nesfatin-1; and a higher level of expression in SAT (p < 0.05 or p < 0.01). Fasting insulin (FI) (b = 0.317, p= 0.022) and body mass index (BMI) before delivery (b = 0.367, p=0.008) were independently associated with serum nesfatin-1. Nesfatin-1 was the independent risk factor for GDM. CONCLUSIONS: The GDM group had higher levels of maternal serum and cord blood nesfatin-1, and greater nesfatin-1 expression in SAT. Nesfatin-1 is closely related to obesity and IR in pregnancy. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/28361552/Serum_levels_of_nesfatin_1_are_increased_in_gestational_diabetes_mellitus_ L2 - http://www.tandfonline.com/doi/full/10.1080/09513590.2017.1306849 DB - PRIME DP - Unbound Medicine ER -